# US 2019/0167576 A1 · Use of high affinity monoclonal antibody product binders to increase the duration of action of therapeutic monoclonal antibody products in a biologic tissue

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167576 A1
- Document ID: US20190167576A1
- Status: Published application
- Kind: A1
- Application number: 16/325,279
- Filed: 2017-09-06
- Published: 2019-06-06
- Earliest claimed: 2016-09-08
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Ira Hyman Schachar
- Web page: https://patentgrep.com/patent/US20190167576A1

## CPC

- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 39/44: Antibodies bound to carriers
- A61K 47/66: the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K 47/68: the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61P 27/02: Ophthalmic agents
- C07K 14/31: from Staphylococcus (G)
- C07K 14/315: from Streptococcus (G), e.g. Enterococci
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 16/22: against growth factors {; against growth regulators}
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/01: containing a localisation/targetting motif
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/70: containing domain for protein-protein interaction
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

An anchor molecule is provided that (1) binds monoclonal antibody products with high affinity and (2) is anchored in a biologic tissue of interest. Therapeutic antibodies can either be delivered to the biologic tissue before, during, or after the delivery of the anchor molecule. Because the present invention binds monoclonal antibody products and is anchored in a biologic tissue, the result is that monoclonal antibody products are also anchored in a biologic tissue.

## Claims

### Claim 1

An anchor molecule, comprising two functional regions or moieties: (1) a region or moiety that binds a therapeutic antibody or fragment thereof with a dissociation constant (KD) less than 10−6 M, and (2) a region or moiety that anchors the molecule in a biologic tissue of interest; wherein the anchor molecule when delivered to the biologic tissue of interest in combination with a therapeutic monoclonal antibody acts to retain the therapeutic monoclonal antibody in the tissue, thereby increasing the duration of action of the therapeutic monoclonal antibody.

### Claim 2 (depends on 1)

The anchor molecule of claim 1, wherein the antibody binding region binds to an Fc region of a therapeutic antibody.

### Claim 3 (depends on 2)

The anchor molecule of claim 2, wherein the Fc region is of human IgG class.

### Claim 4 (depends on 2)

The anchor molecule of claim 2, wherein the Fc region is of human IgG1 class.

### Claim 5 (depends on 2)

The anchor molecule of claim 2, where in the Fc region is recombinant.

### Claim 6 (depends on 1)

The anchor molecule of claim 1, where in the antibody binding region or moiety binds to a FAB region of a therapeutic antibody.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The anchor molecule of any of claims 1-6, wherein the dissociation constant (KD) is less than 10−7M.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

The anchor molecule of any claims 1-6, wherein the dissociation constant (KD) is less than 10−9 M.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6)

The anchor molecule of any claims 1-6, wherein the dissociation constant (KD) is less than 10−9 M.

### Claim 10 (depends on 1)

The anchor molecule of claim 1, wherein the region or moiety that binds a therapeutic antibody is Protein A or a derivative thereof.

### Claim 11 (depends on 1)

The anchor molecule of claim 1, wherein the region or moiety that binds a therapeutic antibody is the Z-domain of Protein A or a derivative thereof (SEQ ID NO: 3).

### Claim 12 (depends on 1)

The anchor molecule of claim 1, wherein the region or moiety that binds a therapeutic antibody is a minimized form of the Z-domain of Protein A or a derivative thereof (SEQ ID NO: 1).

### Claim 13 (depends on 1)

The anchor molecule of claim 1, wherein the region or moiety that binds a therapeutic antibody is a derivative of Protein A that has been stabilized with cysteine residues to prevent degradation and/or enhance binding affinity (SEQ ID NO: 2).

### Claim 14 (depends on 1)

The anchor molecule of claim 1, wherein the region or moiety that binds a therapeutic antibody comprises an amino acid sequence based on the binding domain of Protein A (SEQ ID NO: 1, 2, 3, 6, 7, 8, 9, 10, 11, 12, 13, 14).

### Claim 15 (depends on 1)

The anchor molecule of claim 1, wherein the region or moiety that binds a therapeutic antibody comprises a small molecule.

### Claim 16 (depends on 15)

The anchor molecule of claim 15, wherein the small molecule is based on the binding domain of Protein A or a derivative thereof.

### Claim 17 (depends on 16)

The anchor molecule of claim 16, wherein the region or moiety that binds a therapeutic antibody comprises a triazine based small molecule.

### Claim 18 (depends on 17)

The anchor molecule of claim 17, wherein the region or moiety that binds a therapeutic antibody comprises a triazine based compound from FIG. 11, 12, 13, 14, 15.

### Claim 19 (depends on 15)

The anchor molecule of claim 15, wherein the region or moiety that binds a therapeutic antibody is 1,3-bis({4-[(3-aminophenyl)amino]-6-[(2-hydroxyethyl)amino]-1,3,5-triazin-2-yl}amino)propan-2-ol (compound 1)

### Claim 20 (depends on 15)

The anchor molecule of claim 15, wherein the region or moiety that binds a therapeutic antibody is 2-({4-[(3-aminophenyl)amino]-6-({2-[4-({4-[(3-aminophenyl)amino]-6-{[2-(4-aminophenyl)ethyl]amino}-1,3,5-triazin-2-yl}amino)phenyl]ethyl}amino)-1,3,5-triazin-2-yl}amino)ethan-1-ol (compound 2).

### Claim 21 (depends on 1)

The anchor molecule of claim 1, wherein the region or moiety that binds a therapeutic antibody is based on Protein G or a derivative thereof.

### Claim 22 (depends on 21)

The anchor molecule of claim 21, wherein the derivative of Protein G is based on the C3 domain of Protein G or a derivative thereof (SEQ ID NO: 4)

### Claim 23 (depends on 1)

The anchor molecule of claim 1, wherein the region or moiety that binds a therapeutic antibody is based on a non-immunoglobulin scaffold

### Claim 24 (depends on 23)

The anchor molecule of claim 23, wherein the non-immunoglobulin scaffold is based on the Sac7d protein or a derivative thereof (SEQ ID NO: 5)

### Claim 25 (depends on 23)

The molecule of claim 23, wherein affinity maturation or structure based design is used to enhance binding affinity between the non-immunoglobulin scaffold and the therapeutic antibody.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The anchor molecule of any of claims 1-25, wherein the region or moiety that anchors the molecule in a biologic tissue of interest is covalently joined to the region or moiety that binds a therapeutic antibody.

### Claim 27 (depends on 26)

The anchor molecule of claim 26, wherein the region or moiety that anchors the molecule in a biologic tissue does so by binding to the biologic tissue of interest

### Claim 28 (depends on 26)

The anchor molecule of claim 26, wherein the binding to the biologic tissue of interest is non-covalent.

### Claim 29 (depends on 28)

The anchor molecule of claim 28, wherein the binding to the biologic tissue is mediated through a peptide.

### Claim 30 (depends on 29)

The anchor molecule of claim 29, wherein the peptide binds to hyaluronic acid.

### Claim 31 (depends on 30)

The anchor molecule of claim 30, wherein the peptide is a LINK domain.

### Claim 32 (depends on 31)

The anchor molecule of claim 31, wherein the LINK domain comprises the amino acid sequence set forth in SEQ ID NO:22.

### Claim 33 (depends on 30)

The anchor molecule of claim 30, wherein the peptide is a Hyaluronic Acid Binding Protein (HABP).

### Claim 34 (depends on 33)

The anchor molecule of claim 33, wherein the HABP comprises an amino acid sequence set forth in SEQ ID NO: 23, 24, 25, 26, or 27.

### Claim 35 (depends on 30)

The anchor molecule of claim 30, wherein the peptide is a poly-arginine sequence.

### Claim 36 (depends on 30)

The anchor molecule of claim 30, wherein the peptide is a poly-lysine sequence.

### Claim 37 (depends on 29)

The anchor molecule of claim 29, wherein the peptide binds to type II collagen

### Claim 38 (depends on 29)

The anchor molecule of claim 29, wherein the peptide binds type IV collagen.

### Claim 39 (depends on 30)

The anchor molecule of claim 30, wherein the peptide binds the alpha-3 subunit of type IV collagen.

### Claim 40 (depends on 29)

The anchor molecule of claim 29, wherein the peptide is a non-immunogloblin scaffold.

### Claim 41 (depends on 40)

The anchor molecule of claim 40, wherein the non-immunoglobulin has undergone affinity maturation to specifically bind to the biologic tissue of interest.

### Claim 42 (depends on 28)

The anchor molecule of claim 28, wherein the region or moiety that anchors the molecule in a biologic tissue of interest comprises one or more guanidinium groups.

### Claim 43 (depends on 25)

The anchor molecule of claim 25, wherein the region or moiety that anchors the molecule in a biologic tissue is a polymer.

### Claim 44 (depends on 41)

The anchor molecule of claim 41, wherein the polymer is biodegradable.

### Claim 45 (depends on 44)

The anchor molecule of claim 44, wherein the biodegradable polymer is hyaluronic acid

### Claim 46 (depends on 44)

The anchor molecule of claim 44, wherein the biodegradable polymer is chitosan

### Claim 47 (depends on 44)

The anchor molecule of claim 44, wherein the biodegradable polymer is poly (lactic-co-glycolic acid (PLGA)

### Claim 48 (depends on 41)

The anchor molecule of claim 41, wherein the polymer is non-biodegradable.

### Claim 49 (depends on 48)

The anchor molecule of claim 48, wherein the polymer is poly(methyl methacrylate) (PMMA)

### Claim 50 (depends on 26)

The anchor molecule of claim 26, wherein the binding to the tissue of interest is covalent.

### Claim 51 (depends on 50)

The anchor molecule of claim 50, wherein the binding to the tissue of interest is mediated through N-Hydroxysuccinimide (NHS).

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

A method for treating a tissue in individual with a therapeutic antibody, the method comprising:
delivering to the tissue an effective dose of an anchor molecule according to any of claims 1-51, in combination with an effective dose of the therapeutic antibody; wherein the duration of action of the therapeutic antibody is increased relative to the duration of action in the absence of the anchor molecule.

### Claim 53 (depends on 51)

The method of claim 51, wherein the therapeutic antibody comprises a monoclonal antibody product

### Claim 54 (depends on 51)

The method of claim 51, wherein the therapeutic antibody contains a human IgG Fc region.

### Claim 55 (depends on 51)

The method of claim 51, wherein the therapeutic antibody contains a human IgG1 Fc region.

### Claim 56 (depends on 51, 52, 53, 54, 55)

The method of any claims 51-55, wherein the biologic tissue is the vitreous cavity of the eye.

### Claim 57 (depends on 51, 52, 53, 54, 55)

The method of any claims 51-55, wherein the anchor molecule is delivered either before, during, or after delivery of the therapeutic antibody.

### Claim 58 (depends on 56)

The method of claim 56, wherein the anchor molecule is delivered through an intraocular injection.
